Related Experiment Video
Updated: Jun 22, 2026

An Unpredictable Chronic Mild Stress Protocol for Instigating Depressive Symptoms, Behavioral Changes and Negative Health Outcomes in Rodents
Published on: December 2, 2015
Persistent comorbid symptoms of depression and anxiety predict mortality in heart disease
Lynn V Doering1, Debra K Moser2, Barbara Riegel3
1University of California, Los Angeles Los Angeles, CA, United States.
Insights
Persistent anxiety and depression significantly increase mortality risk in patients with ischemic heart disease. Comorbid symptoms, but not isolated ones, were linked to a higher risk of death.
Area of Science:
- Cardiology
- Psychiatry
- Public Health
Background:
- Anxiety and depression are linked to cardiac events and mortality post-acute coronary syndromes.
- The impact of persistent, comorbid anxiety and depression on mortality in ischemic heart disease (IHD) patients is unknown.
Purpose of the Study:
- To determine the prevalence of persistent comorbid depressive and anxious symptoms in IHD patients.
- To evaluate the effect of these persistent symptoms on mortality.
Main Methods:
- Prospective, longitudinal cohort study with 12-month follow-up of 2325 IHD patients.
- Symptom assessment at enrollment and 3 months using validated questionnaires (Multiple Adjective Affect Checklist, Brief Symptom Inventory).
Main Results:
- 61.7% of patients had persistent depressive, anxious, or comorbid symptoms at 3 months.
- Persistent comorbid symptoms were associated with significantly higher mortality (p=.029).
- Comorbid symptoms increased mortality risk (OR 2.35), while isolated symptoms did not.
Conclusions:
- Persistent anxiety and depression symptoms substantially elevate the risk of death in IHD patients.
- Further research into shared and distinct pathways and treatments for these conditions is warranted.
Background:
Incident anxiety and depression are associated separately with cardiac events and mortality in patients after acute coronary syndromes, but the influence of persistent comorbid depression and anxiety on mortality remains unknown. The purpose of this study was to determine the prevalence of comorbid persistent depressive and anxious symptoms in individuals with ischemic heart disease and to evaluate effects on mortality.
Methods:
Prospective, longitudinal cohort design in the context of a randomized trial to decrease patient delay in seeking treatment for ischemic heart symptoms (PROMOTION trial) was used, with twelve-month follow-up of 2325 individuals with stable ischemic heart disease. Participants were assessed on enrollment and at 3 months using the Multiple Adjective Affect Checklist and the Brief Symptom Inventory for depressive and anxious symptoms, respectively.
Results:
At 3 months, 608 individuals (61.7%) reported persistent symptoms of depression, anxiety, or both. Three hundred seventy-nine (42.5%) and 1056 (45.4%) had persistent anxious and depressive symptoms, respectively. Those with persistent, comorbid symptoms had higher mortality compared to others (p=.029). The combined presence of anxious and depressive symptoms contributed significantly to mortality when compared to symptom-free participants (OR 2.35, 95% CI 1.23-4.47, p=.010). The presence of persistent depressive symptoms only and persistent anxious symptoms only were not associated with death, when other demographic and clinical variables were considered.
Conclusions:
Persistent symptoms of anxiety and depression increased substantially the risk of death in patients with ischemic heart disease. Future research into shared and unique pathways and treatments is needed.
Related Concept Videos
Stress and Mental Health
Individuals with depression often experience challenges in both their personal and professional...
Psychoneuroimmunology: Cardiovascular Disease
A key area of focus in PNI is the relationship between stress and coronary...
Depressive Disorders: MDD and Dysthymia
Coronary Artery Disease I: Introduction
Psychoneuroimmunology: Diabetes and Cancer
Panic Disorder